Blog
RSS FeedPosted by Michael Wonder on 29 Mar 2017
German Federal Joint Committee (G-BA) confirms additional benefit of anti-cancer agent Kisplyx (lenvatinib mesylate) in treatment of advanced renal cell carcinoma
28 March 2017 - Eisai announced today that the German Federal Joint Committee (G-BA) has confirmed the additional benefit of in-house ...
Posted by Michael Wonder on 12 Mar 2017
Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data
12 March 2017 - This study determined methodological requirements for health-related quality of life measurement and data presentation in the early ...
Posted by Michael Wonder on 08 Mar 2017
Germany to scrap plan to lower prices of new drugs-lawmakers
6 March 2017 - Germany's ruling coalition will scrap plans announced last year to lower prices of newly launched drugs ...
Posted by Michael Wonder on 01 Mar 2017
Palbociclib in advanced breast cancer: disadvantages in certain patients
1 March 2017 - More frequent severe side effects in first-line therapy after menopause/missing data for other patients. ...
Posted by Michael Wonder on 06 Jan 2017
German IQWiG confirms additional benefit for Kisplyx (lenvatinib mesylate) in combination with everolimus for the treatment of advanced renal cell carcinoma
4 January 2017 - Approximately 15,000 people in Germany develop renal cell carcinoma every year. ...
Posted by Michael Wonder on 03 Jan 2017
Germany’s model for drug price regulation could work in the US
29 December 2016 - Donald Trump and Hillary Clinton agreed on almost nothing during the 2016 presidential campaign — but ...
Posted by Michael Wonder on 02 Jan 2017
Bronchial carcinoma: additional use of crizotinib not seen
2 January 2017 - The dossier does not contain any suitable data for patients with ROS1 positive non-small-cell lung cancer. ...
Posted by Michael Wonder on 19 Dec 2016
Vertex announces German reimbursement agreement for Orkambi (lumacaftor with ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation
19 December 2016 - Vertex Pharmaceuticals today announced it has reached a pricing and reimbursement agreement for Orkambi (lumacaftor with ...
Posted by Michael Wonder on 06 Dec 2016
Considerable additional benefit of Eisai's Halaven (eribulin mesylate) in advanced liposarcoma confirmed by the German Federal Joint Committee
4 December 2016 - Eribulin mesylate has shown unprecedented survival benefit in advanced liposarcoma in pivotal phase III trial. ...
Posted by Michael Wonder on 16 Nov 2016
Pembrolizumab in lung cancer: evidence of considerable additional benefit
16 November 2016 - Significant advantages when compared to docetaxel. ...
Posted by Michael Wonder on 16 Nov 2016
Trifluridine-tipiracil combination in colorectal cancer: additional benefit only for some patients
16 November 2016 - Low benefit for patients with K-RAS wild type; survival benefits, but significant side effects and missing ...
Posted by Michael Wonder on 14 Nov 2016
Bayer warns planned German price curbs may restrict drug access
14 November 2016 - Germany looking at revenue ceiling for drugs in first year. ...
Posted by Michael Wonder on 19 Oct 2016
EU court quashes German prescription drug price floor
19 October 2016 - Europe's highest court has ruled Germany's floor on retail prescription drug prices violates free trade in ...
Posted by Michael Wonder on 17 Oct 2016
Sofosbuvir with velpatasvir in chronic hepatitis C: hint of added benefit in two of ten subindications
17 October 2016 - Historical comparisons and considerations of individual study arms unsuitable for conclusions on the other research questions. ...
Posted by Michael Wonder on 17 Oct 2016
Emtricitabine/rilpivirine/tenofovir alafenamide in HIV: added benefit not proven
17 October 2016 - Research questions on adolescents not investigated/evidence on components not simply transferable to the combination. ...